SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Mergers and acquisitions

The pharmaceutical industry seems besieged on all sides, with declining R&D productivity, expiring patents on blockbuster products and relentless downward pricing pressure forcing companies to look closely at the bottom line. One affect of this onslaught has been an upsurge in the level of M&A activity as players within the industry consolidate to cut costs, expand research pipelines and lengthen geographic reach.

Actavis welcomes AZ in boosting its LAMA/LABA

06-Aug-2014 - Actavis says it is excited to partner with AstraZeneca over its long-acting muscarinic antagonist/beta-agonist (LAMA/LABA) fixed dose combination respiratory drug following the latter’s acquisition of Almirall.

AstraZeneca coughs up $875m for Almirall to support asthma/COPD pipeline

04-Aug-2014 - AstraZeneca has bolstered its respiratory portfolio and added new bronchodilator technologies through the $875m (€650m) acquisition of Almirall.

Anti-addiction film resilient to generics, says Reckitt Benckiser

29-Jul-2014 - Reckitt Benckiser’ opioid addiction drug Suboxone delivered by sublingual film has shown a 'surprising' level of resilience against generic competition, the firm says as it plans to spin-out its pharmaceutical business....

Ben Venue assets will bolster sterile injectables network, says Hikma

28-Jul-2014 - Hikma has bought defunct manufacturer Ben Venue and says it could reactivate the site in the long-term, despite the transfer of equipment across its sterile injectables network.

UPDATE

Sterile injectables M&A could indicate return to in-house production

22-Jul-2014 - Drugmakers are bringing sterile injectables capacity back in-house according to a Frost & Sullivan analyst, who says industry risk aversion is the key driver.

Allergan further fends off Valeant with 1,500 job cuts, M&A projections

22-Jul-2014 - Botox maker Allergan announced sales and earnings per share growth above the high end of its expectations, but it will cut 1,500 jobs, or about 13% of its workforce as...

Actavis cuts down Forest as $28bn acquisition closes

10-Jul-2014 - Actavis says it is closing facilities in St. Louis, Missouri affecting 190 jobs a week after completing the $28bn (€21bn) acquisition of Forest Laboratories.

M+W sells automation biz to ATS for $350m

08-Jul-2014 - M+W says a lack of synergies with its engineering and construction business drove the decision to sell its automation divison to ATS for €255m ($348m).

Teva's 70+ manufacturing sites could be halved in efficiency drive

12-Jun-2014 - Teva could halve its manufacturing network as part of its $2bn-a-year efficiency programme says CFO Eyal Desheh, with most cuts hitting its core generics business.

Merck's $3.85bn HCV acq focused on 'valuable' nucleotide pipeline

10-Jun-2014 - Merck & Co. says the $3.85bn (€2.8bn) acquisition of Idenix will springboard its oral hepatitis C programme but according to an analyst is unlikely to threaten Gilead’s $1,000 pill Sovaldi.

AstraZeneca bid Pfizzles out as deadline passes

27-May-2014 - Pfizer has confirmed it has dropped a £69bn ($118bn) bid to buy fellow pharma giant AstraZeneca following yesterday’s acquisition deadline.

Bayer buys Merck & Co.'s OTC business for $14.2bn

06-May-2014 - Bayer says it will become the OTC leader in North America having acquired Merck & Co.’s consumer health business for $14.2bn (€10.2bn), in the latest shift in Big Pharma assets....

Pfizer says manufacturing will stay in UK if it buys AstraZeneca

05-May-2014 - Pfizer will keep a “substantial” level of manufacturing in the UK if it takes over AstraZeneca, said the CEO in a letter to the country’s Prime Minister.

Endo acquires migraine treatment, needle-free delivery system for $85M

28-Apr-2014 - Endo Pharmaceuticals, which previously lost a bid to acquire a migraine treatment, has now acquired worldwide rights to Sumavel DosePro (sumatriptan injection) for subcutaneous use, which is a needle-free delivery system for...

AZ refuses $100bn bid, but Pfizer ‘confident’ of ‘compelling’ offer

28-Apr-2014 - AstraZeneca says Pfizer has “very significantly undervalued” the company after confirming rumours it had received an offer worth £59bn ($100bn).

Opko acquires Israeli-made dry powder inhaler to treat respiratory disorders

24-Apr-2014 - Opko Health has agreed to acquire Inspiro Medical, an Israeli medical device company developing a new platform to deliver small molecule drugs such as corticosteroids and beta agonists or larger molecules...

INFOGRAPHIC

AZ for $100bn? Pfizer could buy Azerbaijan and keep the change

22-Apr-2014 - With Pfizer rumoured to be on the brink of a mega-merger with AstraZeneca, in-Pharmatechnologist.com brings you an interactive view of what £60bn ($101bn) could get.

Albemarle to sell ibuprofen business to SI Group

17-Apr-2014 - Albemarle has agreed to sell its ibuprofen business to US chemical intermediates firm SI Group in a deal that will also see it divest the anaesthetic agent, propofol.

UPDATE

Sun Pharma's $3.2bn Ranbaxy acq: 'Compliance first, synergies later'

07-Apr-2014 - Regulatory compliance will be the number one focus for Sun Pharma, the company says, following its $3.2bn (€2.3bn) takeover of Indian generics firm Ranbaxy.

Lupin: Mexican buy a bridgehead to generics and API growth

01-Apr-2014 - Lupin has bought Mexican eye drugmaker Grin in a deal that gives it a “bridgehead” to grow its API and generics business in the region.

Hospira edges closer to completion of Orchid API deal in India

18-Mar-2014 - The Board of Directors at Indian firm Orchid has approved the sale of its API business to Hospira, bringing the acquisition a step closer to completion.

People on the Move

People on the Move: Pharma movers and shakers

17-Mar-2014 - Twin changes at AstraZeneca's MedImmune kick off this week's gallery, as well as jobs news from Europe

UPDATE 1

Actavis to acquire Forest labs in $25bn takeover

18-Feb-2014 - Actavis has confirmed it will acquire Forest Laboratories in a deal worth up to $25bn (€18bn) following rumours last night.

Targeted drug delivery driving partnerships, says expert

06-Feb-2014 - An increased trend in dealmaking for targeted drug delivery last year will continue to drive partnerships in 2014, according to a pharmaceutical partnering expert.

Lupin buys Dutch delivery tech firm for injectables entry

03-Feb-2014 - Lupin Ltd has bought Dutch delivery technology company Nanomi BV in a deal that moves the Indian generics firm into the complex injectables space.

Key Industry Events

 

Access all events listing

Our events, Events from partners...